GLG News by Pharmacists (US)

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Rx Savings with Generic vs Branded Medications

March 28, 2011

Analysis of:Buying Brand-Name Drugs Over Generics Raises Medicaid Costs | www.bloomberg.com

With dollar shortfalls for Rx benefits, controlling drug costs is imperative. By utilizing a strict formulary of covered products, along with clear, real time messaging to the pharmacies,  the generic fill rate (GFR) will rise. With a higher GFR, savings is attained.

David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.

CVS vs. Walgreen's and the latest....

June 12, 2010

As a consultant and clinical pharmacist with over 30 years experience, I am glad someone.... and in this case... Walgreen's finally woke up to fees that are insulting low and a losing proposition. It has been well established the the "average expense to dispense a prescription" (the pharmacy's actual costs including rent, payroll, overhead, etc) is in the $10 range per prescription. Why would any pharmacy sign a contract with a fee of $1.50 per prescription?

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Lupin's opportunity to drop the Lotrel margin!

February 15, 2010

Analysis of:Lupin gets US FDA approval for hypertension capsules | www.pharmabiz.com

The approval of Lupin's generic Lotrel line will create one more player in a field that is currently not very crowded. Yet, don't expect the other players to not react! Generic Lotrel is currently priced relatively high compared to other multi-source hypertensive products.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Cetirizine OTC liquid. A day late and a dollar short.

February 8, 2010

Analysis of:Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

Why the delay? Teva, Taro, and Perrigo all have strong footholds in this market. Rx and OTC competition remains strong, thus what would allow a new player to grow quickly outside of eroding the price market?

Aemad AslamPresidentMindPharma

Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone

April 13, 2009

Analysis of:Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com

Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return to normal supply levels of Oxycodone may occur in approximately 2 months, during which time Sun Pharma can capitalize on the shortage by securing longer term contracts with wholesalers.

Aemad AslamPresidentMindPharma

Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011

March 5, 2009

Analysis of:Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com

Forest's Lexapro commands a $2.5+ billion USD market share, just in the US.  Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA.  Additionally, despite being a brand name product, Lexapro holds an 8%+ year over year increase in the past 3 years.  Hence, the market for the drug in September of 2011 when the patent runs out will be closer to a $3 billion market.                

Aemad AslamPresidentMindPharma

Teva's Generic Imitrex commands market of Sumatriptan

February 26, 2009

Analysis of:Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com

With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets.  Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the generic's sales.  Already, different wholesalers are reporting a backorder on Teva's generics.  Additionally, Teva's pricing point is very favorable to itself, despite Dr Reddy's prior entrance.

Aemad AslamPresidentMindPharma

Acquisitions of Indian Pharma on the extended horizon by Brand name pharma

February 23, 2009

Analysis of:Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com

Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers.  However, this is not an immediate concern.  I would see more consolidations in the US and other Western markets first. 

Aemad AslamPresidentMindPharma

Sun Pharma - much stronger with acquisitions including Taro

February 17, 2009

Analysis of:As valuations dip, Sun Pharma is in M&A mode | economictimes.indiatimes.com

Sun Pharma is attempting to gain market share in the world largest market - the US market.  Sun Pharma is clearly expanding it product base with venturing into topical (dermatological) and pediatric segments, and with vertical integration as with raw materials suppliers.  Sequentially, I would see SunPharma to be a leader in the US market within this decade, unless other Indian manufacturers encroach in this market.                     

Aemad AslamPresidentMindPharma

Aurobindo's Terbinafine Tablets? Not a news maker

January 26, 2009

Analysis of:Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com

Aurobindo's approval of Terbinafine tablets is already entering a saturated market as the tenth entrant.  Accordingly, with strong pressures from other Indian manufacturers as Dr Reddy's and Wockhardt, this has very little profit margin potential.  Such reduced pricing is aiding the wholesalers as McKesson (MCK) or Cardinal (CAH) by negotiating an even lower acquisition cost.  Reduced pricing is already evident, as Terbinafine has been on Walmart's (WMT) $4 generic list for some time.

Page : 123Next1 to 10 of 29